consultants-lab.com

What It Is

Medical Source is a provider of clinical laboratory consulting services that has been operating since 1992. The website focuses on its one-stop launch solution for urine toxicology laboratories. It is not a typical SaaS platform; instead, it bundles immunoassay screening, LC-MS/MS confirmation, pre-validated consumables, compliance, instrument selection, LIS/EMR integration, staff training, and reimbursement consulting into a laboratory setup service.

Core Capabilities

Its core workflow is divided into three layers: the first layer uses CEDIA and DRI immunoassays for initial screening, covering 40+ drug classes, with results available within 30 minutes; the second layer uses triple quadrupole mass spectrometry with a DART ion source for confirmation, claiming to process 96 samples in about 42 minutes; the third layer uses pre-plated 96-well consumables, NIST-traceable standards, and quality controls to reduce manual preparation and improve efficiency. Beyond toxicology labs, the text also mentions molecular testing, PGx/CGx, instrument selection, CLIA/COLA compliance, QA, SOPs, inspection preparation, recruiting and training, and profitability/reimbursement consulting.

Pricing and Business Model

The website does not publish packages or prices, and it clearly states that startup costs vary depending on testing volume, instruments, facilities, and staffing needs. It offers free feasibility consulting, volume projections, test menu assessment, and financial modeling, and says it can help with financing. For buyers, quotes and ROI calculations must be obtained through consultation.

Pros and Cons

Its strengths are that it covers the full end-to-end path of building a lab from zero to one, while emphasizing vendor neutrality, service across all 50 U.S. states, long-term advisory relationships, and integration with LIS/EMR/billing modules. For healthcare organizations without lab-building experience, this type of turn-key service can reduce organizational complexity. The drawbacks are that the publicly available materials lean more toward marketing and technical overview, with little information on standardized pricing, contract scope, software interface, permission systems, data security, APIs, and other enterprise software evaluation criteria. At the same time, its compliance and reimbursement logic is clearly centered on U.S. CLIA/COLA, Medicare, and private payers, so it may not apply to other countries.

Who It’s For and Access from China

It is better suited to U.S.-based pain management, addiction treatment, family medicine, emergency care, reference laboratories, physician-owned laboratories, and other organizations that want to build their own urine toxicology testing capabilities. Access from China cannot be determined from the main text, so it is marked as unknown.